Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial. Issue 216 (August 2022)

• Record Type: Journal Article
• Authors: Rashidi, Farid; Barco, Stefano; Rezaeifar, Parisa; Sadeghipour, Parham; Ghodrati, Samad; Bakhshandeh, Hooman; Mousavi-Aghdas, Seyed Ali; Sadeghi, Armin; Sharifi, Akbar; Valizadeh, Hamed; Mikaeili, Haleh; Rafiee, Farnaz; Navarbaf, Zahar; Farajian, Gita; Mahmoodpoor, Ata; Bikdeli, Behnood; Ansarin, Khalil
• Is Part Of: Thrombosis research. Issue 216(2022)
• Page Start: 125
• Page End: 128
• Publication Date: 2022-08
• Subjects: Coronavirus disease 2019 (COVID-19) -- Acute respiratory distress syndrome (ARDS) -- Tissue plasminogen activator (tPA) -- Fibrinolytic therapy -- Anticoagulation; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2021.12.003
• Languages: English
• ISSNs: 0049-3848

Abstract

Highlights: Widespread microthrombosis is considered as an etiology for impaired oxygenation in patients with COVID-19 with ARDS. Systemic thrombolytic versus prophylactic- and therapeutic-dose anticoagulation were compared in present study. Systematic thrombolytic therapy did not improve oxygenation in critically ill patients with COVID-19.